JP2019528769A5 - - Google Patents

Download PDF

Info

Publication number
JP2019528769A5
JP2019528769A5 JP2019518049A JP2019518049A JP2019528769A5 JP 2019528769 A5 JP2019528769 A5 JP 2019528769A5 JP 2019518049 A JP2019518049 A JP 2019518049A JP 2019518049 A JP2019518049 A JP 2019518049A JP 2019528769 A5 JP2019528769 A5 JP 2019528769A5
Authority
JP
Japan
Prior art keywords
nucleic acid
acid molecule
human
cell
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019518049A
Other languages
English (en)
Japanese (ja)
Other versions
JP6887492B2 (ja
JP6887492B6 (ja
JP2019528769A (ja
Filing date
Publication date
Priority claimed from PCT/US2017/055133 external-priority patent/WO2018067697A1/en
Application filed filed Critical
Publication of JP2019528769A publication Critical patent/JP2019528769A/ja
Publication of JP2019528769A5 publication Critical patent/JP2019528769A5/ja
Priority to JP2021083808A priority Critical patent/JP7106715B2/ja
Publication of JP6887492B2 publication Critical patent/JP6887492B2/ja
Publication of JP6887492B6 publication Critical patent/JP6887492B6/ja
Application granted granted Critical
Priority to JP2022112159A priority patent/JP2022160443A/ja
Priority to JP2024013162A priority patent/JP2024059633A/ja
Priority to JP2025247640A priority patent/JP2026062707A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019518049A 2016-10-04 2017-10-04 遺伝子改変細胞で使用するための共刺激ドメイン Active JP6887492B6 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2021083808A JP7106715B2 (ja) 2016-10-04 2021-05-18 遺伝子改変細胞で使用するための共刺激ドメイン
JP2022112159A JP2022160443A (ja) 2016-10-04 2022-07-13 遺伝子改変細胞で使用するための共刺激ドメイン
JP2024013162A JP2024059633A (ja) 2016-10-04 2024-01-31 遺伝子改変細胞で使用するための共刺激ドメイン
JP2025247640A JP2026062707A (ja) 2016-10-04 2025-12-12 遺伝子改変細胞で使用するための共刺激ドメイン

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662403880P 2016-10-04 2016-10-04
US62/403,880 2016-10-04
US201762501475P 2017-05-04 2017-05-04
US62/501,475 2017-05-04
US201762556199P 2017-09-08 2017-09-08
US62/556,199 2017-09-08
PCT/US2017/055133 WO2018067697A1 (en) 2016-10-04 2017-10-04 Co-stimulatory domains for use in genetically-modified cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021083808A Division JP7106715B2 (ja) 2016-10-04 2021-05-18 遺伝子改変細胞で使用するための共刺激ドメイン

Publications (4)

Publication Number Publication Date
JP2019528769A JP2019528769A (ja) 2019-10-17
JP2019528769A5 true JP2019528769A5 (enExample) 2020-11-12
JP6887492B2 JP6887492B2 (ja) 2021-06-16
JP6887492B6 JP6887492B6 (ja) 2021-07-14

Family

ID=60382586

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2019518049A Active JP6887492B6 (ja) 2016-10-04 2017-10-04 遺伝子改変細胞で使用するための共刺激ドメイン
JP2021083808A Active JP7106715B2 (ja) 2016-10-04 2021-05-18 遺伝子改変細胞で使用するための共刺激ドメイン
JP2022112159A Pending JP2022160443A (ja) 2016-10-04 2022-07-13 遺伝子改変細胞で使用するための共刺激ドメイン
JP2024013162A Pending JP2024059633A (ja) 2016-10-04 2024-01-31 遺伝子改変細胞で使用するための共刺激ドメイン
JP2025247640A Pending JP2026062707A (ja) 2016-10-04 2025-12-12 遺伝子改変細胞で使用するための共刺激ドメイン

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2021083808A Active JP7106715B2 (ja) 2016-10-04 2021-05-18 遺伝子改変細胞で使用するための共刺激ドメイン
JP2022112159A Pending JP2022160443A (ja) 2016-10-04 2022-07-13 遺伝子改変細胞で使用するための共刺激ドメイン
JP2024013162A Pending JP2024059633A (ja) 2016-10-04 2024-01-31 遺伝子改変細胞で使用するための共刺激ドメイン
JP2025247640A Pending JP2026062707A (ja) 2016-10-04 2025-12-12 遺伝子改変細胞で使用するための共刺激ドメイン

Country Status (8)

Country Link
US (4) US11286291B2 (enExample)
EP (3) EP3757120B8 (enExample)
JP (5) JP6887492B6 (enExample)
AU (4) AU2017338846B2 (enExample)
CA (1) CA3039014A1 (enExample)
DK (2) DK3757120T3 (enExample)
ES (2) ES2811500T3 (enExample)
WO (1) WO2018067697A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015243849B2 (en) 2014-04-10 2020-12-17 Seattle Children's Hospital (dba Seattle Children's Research Institute) Transgene genetic tags and methods of use
JP7162530B2 (ja) 2015-08-07 2022-10-28 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） 固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞
AU2017338846B2 (en) * 2016-10-04 2020-09-24 Precision Biosciences, Inc. Co-stimulatory domains for use in genetically-modified cells
MA46995A (fr) 2016-12-03 2019-10-09 Acerta Pharma Bv Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase
US20200190541A1 (en) * 2017-04-28 2020-06-18 Precision Biosciences, Inc. Methods for reducing dna-induced cytotoxicity and enhancing gene editing in primary cells
CN111225675B (zh) 2017-06-02 2024-05-03 朱诺治疗学股份有限公司 使用过继细胞疗法治疗的制品和方法
US11434290B2 (en) * 2017-06-08 2022-09-06 H. Lee Moffitt Cancer Center And Research Institute, Inc. Chimeric antigen receptors with enhanced NFκB signaling
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
US12240915B2 (en) 2018-08-30 2025-03-04 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
US10918667B2 (en) 2018-11-20 2021-02-16 Innovative Cellular Therapeutics CO., LTD. Modified cell expressing therapeutic agent and uses thereof
WO2020206248A1 (en) 2019-04-03 2020-10-08 Precision Biosciences, Inc. Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir)
US20220204994A1 (en) 2019-04-05 2022-06-30 Precision Biosciences, Inc. Methods of preparing populations of genetically-modified immune cells
WO2021016608A1 (en) 2019-07-25 2021-01-28 Precision Biosciences, Inc. Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus
AU2020333851A1 (en) 2019-08-20 2022-03-31 Precision Biosciences, Inc. Lymphodepletion dosing regimens for cellular immunotherapies
WO2021087305A1 (en) 2019-10-30 2021-05-06 Precision Biosciences, Inc. Cd20 chimeric antigen receptors and methods of use for immunotherapy
EP4069285A1 (en) 2019-12-06 2022-10-12 Precision BioSciences, Inc. Methods for cancer immunotherapy, using lymphodepletion regimens and cd19, cd20 or bcma allogeneic car t cells
US20230346937A1 (en) * 2020-02-13 2023-11-02 Beijing Immunochina Pharmaceuticals Co., Ltd. Optimization of chimeric antigen receptor
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
US20230190780A1 (en) * 2020-05-15 2023-06-22 Precision Biosciences, Inc. Methods for immunotherapy
US20230192807A1 (en) * 2020-05-15 2023-06-22 Precision Biosciences, Inc. Methods for immunotherapy
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
JP2023532864A (ja) * 2020-06-30 2023-08-01 ザ ユニバーシティー コート オブ ザ ユニバーシティー オブ エジンバラ 導入遺伝子発現系
US20260028412A1 (en) 2020-08-10 2026-01-29 Precision Biosciences, Inc. Antibodies and fragments specific for b-cell maturation antigen and uses thereof
WO2022076547A1 (en) 2020-10-07 2022-04-14 Precision Biosciences, Inc. Lipid nanoparticle compositions
EP4284823A1 (en) 2021-01-28 2023-12-06 Precision BioSciences, Inc. Modulation of tgf beta signaling in genetically-modified eukaryotic cells
US11945876B2 (en) * 2021-06-16 2024-04-02 Instil Bio (Uk) Limited Receptors providing targeted costimulation for adoptive cell therapy
WO2022272297A1 (en) * 2021-06-25 2022-12-29 Oxford Biomedica Solutions Llc Adeno-associated virus packaging systems
WO2023064872A1 (en) 2021-10-14 2023-04-20 Precision Biosciences, Inc. Combinations of anti-bcma car t cells and gamma secretase inhibitors
WO2023081767A1 (en) 2021-11-05 2023-05-11 Precision Biosciences, Inc. Methods for immunotherapy
US20250009800A1 (en) 2021-11-16 2025-01-09 Precision Biosciences, Inc. Methods for cancer immunotherapy
US20250041417A1 (en) 2021-12-10 2025-02-06 Precision Biosciences, Inc. Methods for cancer immunotherapy
IL313935A (en) 2021-12-30 2024-08-01 Tr1X Inc CD4+ T cells expressing IL-10 chimeric antigen receptors and uses thereof
WO2024148167A1 (en) 2023-01-05 2024-07-11 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for the human t cell receptor alpha constant region gene
WO2026015450A1 (en) 2024-07-06 2026-01-15 Tr1X, Inc. Cd4+ t cells expressing il-10 and chimeric antigen receptors and uses thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
EP0770129B1 (en) 1994-01-18 2005-11-23 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
CA2196419C (en) 1994-08-20 2007-08-21 Yen Choo Improvements in or relating to binding proteins for recognition of dna
GB9824544D0 (en) 1998-11-09 1999-01-06 Medical Res Council Screening system
US5789538A (en) 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6015832A (en) 1997-12-31 2000-01-18 The Regents Of The University Of Michigan Methods of inactivating bacteria including bacterial spores
US6635676B2 (en) 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US6506803B1 (en) 1999-04-28 2003-01-14 Regents Of The University Of Michigan Methods of preventing and treating microbial infections
US7767216B2 (en) 1999-04-28 2010-08-03 The Regents Of The University Of Michigan Antimicrobial compositions and methods of use
US6559189B2 (en) 1999-04-28 2003-05-06 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US20020061512A1 (en) 2000-02-18 2002-05-23 Kim Jin-Soo Zinc finger domains and methods of identifying same
US20030044787A1 (en) 2000-05-16 2003-03-06 Joung J. Keith Methods and compositions for interaction trap assays
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
US6555674B2 (en) 2000-08-09 2003-04-29 Nsgene A/S JeT promoter
GB0108491D0 (en) 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
AU2003251286B2 (en) 2002-01-23 2007-08-16 The University Of Utah Research Foundation Targeted chromosomal mutagenesis using zinc finger nucleases
US20030232410A1 (en) 2002-03-21 2003-12-18 Monika Liljedahl Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
JP2006502748A (ja) 2002-09-05 2006-01-26 カリフォルニア インスティテュート オブ テクノロジー 遺伝子ターゲッティングを誘発するキメラヌクレアーゼの使用方法
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
WO2007014275A2 (en) 2005-07-26 2007-02-01 Sangamo Biosciences, Inc. Targeted integration and expression of exogenous nucleic acid sequences
EP2650366B1 (en) 2005-10-18 2017-03-22 Precision Biosciences Rationally designed meganucleases with altered sequence specificity and DNA-binding affinity
EP2215223B1 (en) 2007-10-31 2013-05-01 Precision Biosciences, Inc. Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
EP2206723A1 (en) 2009-01-12 2010-07-14 Bonas, Ulla Modular DNA-binding domains
US8465743B2 (en) * 2009-10-01 2013-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
NO2510096T3 (enExample) 2009-12-10 2015-03-21
JP5996630B2 (ja) 2011-04-05 2016-09-21 セレクティスＣｅｌｌｅｃｔｉｓ コンパクトｔａｌｅ−ヌクレアーゼを作製する方法及びその使用
US9272002B2 (en) * 2011-10-28 2016-03-01 The Trustees Of The University Of Pennsylvania Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
SI3300745T1 (sl) * 2013-02-15 2020-01-31 The Regents Of The University Of California Himerni antigenski receptor in postopki njihove uporabe
US10934346B2 (en) 2014-02-14 2021-03-02 Bellicum Pharmaceuticals, Inc. Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12
JP2017519502A (ja) * 2014-06-17 2017-07-20 セレクティスＣｅｌｌｅｃｔｉｓ Ｃｄ１２３特異的多重鎖キメラ抗原受容体
JP6736540B2 (ja) * 2014-07-21 2020-08-05 ノバルティス アーゲー Ｃｌｌ−１キメラ抗原受容体を使用した癌の処置
JP2017522884A (ja) 2014-07-29 2017-08-17 ファイザー・インク がん免疫療法のためのＥＧＦＲｖＩＩＩ特異的キメラ抗原受容体
CA2959168A1 (en) 2014-09-02 2016-03-10 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides
MX2017004603A (es) 2014-10-07 2017-06-30 Cellectis Metodo para modular actividad de celulas inmunes inducidas por car.
WO2016090190A1 (en) * 2014-12-03 2016-06-09 Juno Therapeutics, Inc. Methods and compositions for adoptive cell therapy
KR102923234B1 (ko) 2014-12-19 2026-02-04 다나-파버 캔서 인스티튜트 인크. 키메라 항원 수용체 및 이의 사용 방법
WO2016120218A1 (en) 2015-01-26 2016-08-04 Cellectis ANTI-CLL1 SPECIFIC SINGLE-CHAIN CHIMERIC ANTIGEN RECEPTORS (scCARS) FOR CANCER IMMUNOTHERAPY
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
AU2017338846B2 (en) * 2016-10-04 2020-09-24 Precision Biosciences, Inc. Co-stimulatory domains for use in genetically-modified cells
WO2020206248A1 (en) * 2019-04-03 2020-10-08 Precision Biosciences, Inc. Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir)
WO2021087305A1 (en) * 2019-10-30 2021-05-06 Precision Biosciences, Inc. Cd20 chimeric antigen receptors and methods of use for immunotherapy
EP4069285A1 (en) * 2019-12-06 2022-10-12 Precision BioSciences, Inc. Methods for cancer immunotherapy, using lymphodepletion regimens and cd19, cd20 or bcma allogeneic car t cells

Similar Documents

Publication Publication Date Title
US20250382621A1 (en) Immune effector cell therapies with enhanced efficacy
Gao et al. Therapeutic potential of CRISPR/Cas9 gene editing in engineered T‐cell therapy
Miliotou et al. CAR T-cell therapy: a new era in cancer immunotherapy
JP2017537627A5 (enExample)
Figueroa et al. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy
Liu et al. Applications of immunogenomics to cancer
JP2016502512A5 (enExample)
JP2017535284A5 (enExample)
JP2018029594A5 (enExample)
CN103304638B (zh) 具有抗肿瘤活性的pd-l1亲和肽及其应用
JP2020529841A5 (enExample)
JP2018531014A5 (enExample)
JP2020022456A5 (enExample)
JP2018029595A5 (enExample)
JP2021522820A5 (enExample)
JP2019535262A5 (enExample)
Chang et al. Combination therapy with bispecific antibodies and PD-1 blockade enhances the antitumor potency of T cells
IL292650B2 (en) COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Ra2
RU2015117237A (ru) Химерные антигенные рецепторы м971
RU2018113510A (ru) Химерные рецепторы антигена, нацеленные на psca
JP2016538855A5 (enExample)
JP2016520074A5 (enExample)
JP2018523484A5 (enExample)
JP2017529851A5 (enExample)
JP2018509148A5 (enExample)